Literature DB >> 6962317

The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy.

M L Slevin, E M Piall, G W Aherne, A Johnston, T A Lister.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6962317     DOI： 10.1002/mpo.2950100715

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN： 0098-1532


× No keyword cloud information.
  13 in total

Review 1.  Intrathecal chemotherapy with antineoplastic agents in children.

Authors:  A Ruggiero; V Conter; M Milani; E Biagi; I Lazzareschi; P Sparano; R Riccardi
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Pharmacologic strategies for the treatment of meningeal malignancy.

Authors:  S M Blaney; D G Poplack
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  Treatment of myeloblastic sarcoma in the sacral canal with high-dose cytosine arabinoside.

Authors:  M Barnett; M Richards; C Hamilton; A Lister
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 4.  Current pharmacological treatment approaches to central nervous system leukaemia.

Authors:  S M Blaney; F M Balis; D G Poplack
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.

Authors:  S A Johnson
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

Review 6.  Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis.

Authors:  Gudrun Fleischhack; Ulrich Jaehde; Udo Bode
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma.

Authors:  A Rohatiner; M L Slevin; H S Dhaliwal; J S Malpas; T A Lister
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside.

Authors:  H D Preisler; Y M Rustum; N Azarnia; R Priore
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Intensive consolidation chemotherapy for acute lymphoblastic leukaemia (UKALL X pilot study).

Authors:  C R Pinkerton; A Bowman; H Holtzel; J M Chessells
Journal:  Arch Dis Child       Date:  1987-01       Impact factor: 3.791

10.  AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.

Authors:  L H Lindner; H Ostermann; W Hiddemann; A Kiani; M Würfel; T Illmer; C Karsch; U Platzbecker; G Ehninger; E Schleyer
Journal:  Int J Hematol       Date:  2008-10-04       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.